In 2025, sales are anticipated to grow by a mid-to-high single-digit percentage at CER. Sanofi (SNY) confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER; Sanofi intends to complete a share buyback program in 2025 of EUR 5B of which 72% was already repurchased.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNY:
- Innate Pharma announces EUR 15M capital increase from Sanofi
- Sanofi’s Strong Financial Performance and Promising R&D Pipeline Justify Buy Rating
- Innate Pharma regains rights to Anket, announces potential Sanofi investment
- Sanofi’s Dupixent Gains FDA Approval for Chronic Spontaneous Urticaria
- Trump looking at cutting drug prices to international levels, Reuters says
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue